Monoclonal antibodies to fibroblast growth factor receptor 2

Inventors: Kyung Jin Kim (Cupertino, CA); Wei-Meng Zhao (Palo Alto, CA); Hangil Park (San Francisco, CA); Maximiliano Vasquez (Palo Alto, CA)

Assignee: GALAXY BIOTECH, LLC.

C07K16/2863 G01N33/5759 A61K2039/505 C07K2317/24 C07K2317/33 C07K2317/51 C07K2317/565 C07K2317/92 G01N2333/71

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 12679897
App. No.: 18/182,242
Granted: Jul 14, 2026
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.

Claims (3)

1 . A pharmaceutical composition comprising the antibody produced by the hybridoma deposited as ATCC PTA-9586.

2 . A method of treating cancer in a patient comprising administering to the patient a pharmaceutical composition comprising the antibody of claim 1 .

3 . The method of claim 2 wherein said cancer is gastric cancer.